WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient, socially responsible and sustainable solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec's open-access platform is enabling more than 4,400 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated."
Enabling more than 4,400 Innovative Collaborators from more than 30 Countries
Small Molecule Drug R&D and Manufacturing
Cell Therapy
and Gene Therapy
Drug R&D and Medical
Device Testing
Clinical
Services
Small Molecule Drug R&D and Manufacturing
To Become the Most Comprehensive Capability and Technology Platform in the Global Pharmaceutical and Healthcare Industry
WuXi AppTec Reports Record First-Quarter 2021 Results
WuXi AppTec Reports Strong 2020 Annual Results
WuXi AppTec Completes Acquisition of OXGENE to Further Strengthen Cell and Gene Therapy Service Offerings for Global Customers
WuXi STA to Purchase Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland
WuXi AppTec Recognized by Frost & Sullivan with 2020 Global Customer Value Leadership Award
ViGeneron and WuXi Advanced Therapies Enter Strategic Manufacturing Partnership for Next-Generation Ophthalmic Gene Therapy
